Imagion presents positive new data at World Molecular Imaging Congress

Imagion presents positive new data at World Molecular Imaging Congress Study reports MagSense™ utility as a potential MRI contrast agent MELBOURNE — Imagion…


Biotech Daily — Dr Boreham's Crucible: Imagion Biosystems

Tim Boreham profiles Imagion Biosystems in this 5-1/2 page article. Read the profile.


Finfeed Podcast with Bob Proulx from Imagion Biosystems

Podcast: How Imagion is bringing cancer diagnostics into the 21st century. "According to Imagion Biosystems (ASX:IBX) CEO, Robert Proulx, advancements in…


Imagion Biosystem's August Newsletter

In this issue: FDA "Breakthrough Device Designation" Tox Study Completion WMIC 2019 Poster Q&A with Bob Proulx Read the issue.


Imagion Biosystems features in Next Biotech — One ASX Med-Tech is Set to Transform the $100+Billion Cancer Diagnostic Market

"MagSense is a unique, non-invasive, patent protected technology that fits into myriad addressable cancer diagnostic markets collectively worth $166 billion…


Morgans Under the Microscope Podcast with Bob Proulx

Morgans Senior Analyst Scott Power caught up with Robert Proulx, Chief Executive Officer of Imagion Biosystems, who explained with he joined the company and…


Imagion Biosystems Initiates Regulatory Communications for First-in-Human Study

Imagion Biosystems has filed a Pre-Submission with the U.S. Food and Drug Administration (FDA), the first step is gaining approval to commence its…


Imagion Biosystems receives A$2 million in R&D tax incentives

Imagion Biosystems Limited has received A$2 million in R&D tax incentives from the Australian Tax Office (ATO). In May 2019, the Company reported that it…


Proactiveinvestors Interviews Bob Proulx on FDA Fast Track Status for MagSense™ Imaging

Proactiveinvestors interviews Bob Proulx on what FDA's designation of MagSense™ imaging as a "breakthrough device" means for the company and its investors:…


Imagion Biosystems Receives FDA Breakthrough Device Designation

Imagion Biosystems Limited (ASX: IBX) (the Company), a company dedicated to improving healthcare through the earlier detection of cancer, today announced that…